Female-led ImmuONE bags £2M for 3D human lung model to test drugs — TFN

UK-based biotech company ImmuONE, a University of Hertfordshire spin-out, has secured £2 million in funding. The investment came from the MEIF Proof of Concept & Early Stage Fund, managed by Mercia Ventures, as well as Mercia’s EIS funds and Pioneer Group. ImmuONE has developed a 3D human lung model that can assess the safety of new drugs without animal testing. The funding will enable ImmuONE to move into new headquarters and laboratories, expand capacity, continue research and development, and grow its team. The company's approach involves growing human lower lung tissue and immune cells in a laboratory to create a 3D model, which enables companies to avoid animal testing and test the impact of their products on the small airways and inflammation in the lung.

ImmuONE Raises £2 Million to Advance 3D Human Lung Model for Drug Testing

ImmuONE is a UK-based biotech company founded in 2019 by Dr Abigail Martin and Professor Victoria Hutter. The company, a University of Hertfordshire spin-out, has developed a 3D human lung model that can assess the safety of new drugs without the use of animal testing. Their approach involves growing human lower lung tissue and immune cells in a laboratory to create a 3D model. This allows companies to avoid animal testing and test the impact of their products on the small airways and inflammation in the lung.

ImmuONE is a UK-based biotech company developing a 3D human lung model for drug safety testing without animal testing.

2 years ago

ImmuONE Raises £2 Million to Advance 3D Human Lung Model for Drug Testing

Covered on